Stock CUE CUE BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Cue Biopharma, Inc.

Equities

CUE

US22978P1066

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
1.48 USD -8.64% Intraday chart for Cue Biopharma, Inc. -9.20% -43.94%
Jun. 07 Cue Biopharma, Inc. Appoints Michael J. Fox to the Board of Directors and the Compensation Committee CI
May. 09 Cue Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Evolution of the average Target Price on Cue Biopharma, Inc.

Price target over the last 5 years

History of analyst recommendation changes

1105aabc10dfa4.jcvoXtE33NNqZJI1nKqEcqqnzaXHR2zK6fmeo-OWtjA.wL6BOOFcsLI8J_4H79ntFpvBrpKgLw69rrT3zM7X0Qnqm9A4uGib4hgU4Q~f161cb9c503f47a438da6d59a7e4bd8a

Analyst Recommendations on Cue Biopharma, Inc.

Jefferies Starts Cue Biopharma With Buy Rating MT
Piper Sandler Adjusts Price Target on Cue Biopharma to $8 From $7, Maintains Overweight Rating MT
Cue Biopharma Says Phase 1b Trial of CUE-101 With Pembrolizumab Shows 40% Overall Response Rate MT
Stifel Adjusts Cue Biopharma's Price Target to $8 From $9, Keeps Buy Rating MT
Piper Sandler Starts Cue Biopharma at Overweight With $7 Price Target MT
Oppenheimer Adjusts Cue Biopharma's Price Target to $10 From $26, Maintains Outperform Rating MT
JMP Securities Adjusts Cue Biopharma's Price Target to $15 From $30, Maintains Market Outperform Rating MT
Oppenheimer Adjusts Cue Biopharma's Price Target to $26 From $32, Maintains Outperform Rating MT
Craig-Hallum Adjusts Cue Biopharma's Price Target to $26 From $28, Keeps Buy Rating MT
HC Wainwright Starts Cue Biopharma at Buy with $20 Price Target MT
Craig-Hallum Starts Cue Biopharma at Buy with $28 Price Target MT
CUE BIOPHARMA : Berenberg Starts Cue Biopharma at Buy With $30 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.48 USD
Average target price
9.4 USD
Spread / Average Target
+535.14%
High Price Target
15 USD
Spread / Highest target
+913.51%
Low Price Target
6 USD
Spread / Lowest Target
+305.41%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Cue Biopharma, Inc.

Jefferies & Co.
Piper Sandler
Stifel Nicolaus
Oppenheimer
JMP Securities
Craig-Hallum
HC Wainwright

Ratings for Cue Biopharma, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CUE Stock
  4. Consensus Cue Biopharma, Inc.